BridgeBio fell $2.94 (10%) to $26.88 Friday after proposing Thursday to fully acquire its cardiovascular-focused subsidiary Eidos, which climbed $3.11 (10%) to $35.17 on the news.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,